Pfizer Inc. (PFE)
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
PHILADELPHIA , June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera. Shareholders of PFIZER may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bm.net or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015 or visit: Click Here Berger Montague's investigation is focused on whether Pfizer's Board of Directors breached its fiduciary duties in the manner in which it oversaw the Company's marketing and sale of Depo-Provera, an injectable used for contraception or to treat endometriosis, as well as other indications.
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.
Buy, Sell, Or Hold PFE Stock At $23?
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management's decisions on R&D spending and acquisitions have weighed on Pfizer's stock lately.
3 Low-Priced Dividend Stocks Paying Over 5% Right Now
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.
2 High-Yield Dividend Stocks Yielding Over 6% That'll Pay You to Wait
High-yielding dividend stocks may not be the ticket to superior returns, but they can rank pretty high on the list of nice-to-haves for investors in retirement or those who could use a bit of extra financial flexibility at the end of any given month.
Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"
Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it can reduce risk of colorectal cancer deaths by 51%.
PFE or LLY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Are Investors Undervaluing Pfizer (PFE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Management's focus on non-COVID segments and aggressive cost-cutting initiatives are expected to support margins and EPS growth, trending towards the upper end of FY2025 guidance. Impending LOEs for key drugs ( ~$17B peak revenue by 2026-2030) are a concern, but Pfizer is actively investing in its pipeline, especially oncology and vaccines, to offset this.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature, results from competitors such as Instil Bio are promising. We think Instil Bio, through its low valuation, and Pfizer, given its dividend yield, constitute good Buy opportunities to get exposure to the field.
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
